版本:
中国

BRIEF-Celgene Corp says data presented at ESMO 2016 adds to understanding of Abraxane as therapy for patients with historically challenging solid tumors

Oct 7 Celgene Corp :

* New data being presented from abound trials demonstrate continued benefit of abraxane/carboplatin doublet therapy in NSCLC

* Data presented at ESMO 2016 adds to understanding of Abraxane as a therapy for patients with historically challenging solid tumors

* Latest edition of ESMO lung cancer guidelines have been updated to recommend use of abraxane + carboplatin in patients with stage iv NSCLC Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐